



Prophylactic **TRE**atment **O**f the du**C**tus **A**rteriosus in **P**reterm infants by **A**cetaminophen

With **35 sites open** to recruitment in **12 countries**, TREOCAPA phase III study are progressing well with **172 patients enrolled** to date, **nine countries** having included at least 1 preterm infant



TREOCAPA is a pragmatic multicenter randomized trial.

In the protocol, we mentioned the McNamara's criteria as guidance for rescue therapy. Nevertheless, TREOCAPA is a pragmatic trial, which leaves it to each team to decide on the best care for their patients according to their local practice. Indeed, as the protocol also states, investigators are free to discontinue the study treatment if necessary, and thus implement the care they deem appropriate based on their medical judgement.



Newsletter N° 12 – April 2022

Survey on follow-up and cardiovascular practices

Thank you to all who have participated in the survey on follow-up and cardiovascular practices in your hospital. If you haven't responded yet, there's still time! You will soon receive another email reminder from Melanie Durox inviting you to complete a questionnaire. Please look out for an email from melanie.durox@inserm.fr and send your responses before the survey closes at the end of April. Thanks a lot !

The Treocapa team wishes you a happy easter !

TREOCAPA is a study co-developed with parents and their European representatives.



This study is funded by the c4c project. Find out more here: <https://conect4children.org/>



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.